This trial will compare the safety of tivanisiran sodium eye drops to a placebo in people with dry eye disease, dosed once daily for a year.
- Dry Eye Syndrome
1 Primary · 0 Secondary · Reporting Duration: 1 year
2 Treatment Groups
Tivanisiran sodium ophthalmic solution
1 of 2
Vehicle ophthalmic solution
1 of 2
301 Total Participants · 2 Treatment Groups
Primary Treatment: Tivanisiran sodium ophthalmic solution · Has Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · All Participants · 3 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Who else is applying?
What state do they live in?
What site did they apply to?
|Sylentis Investigative Site||100.0%|
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
- "I use muro 128 every night for my dry eyes"
How many prior treatments have patients received?
Frequently Asked Questions
Where are patients able to participate in this trial?
"There are 24 sites currently running this clinical trial, which are based in Washington, Largo and Asheville as well as 21 other locations. If you enroll in the trial, it would be most convenient to select the site nearest to your location to minimize travel requirements." - Anonymous Online Contributor
Are people still able to sign-up for this experiment?
"According to the listing on clinicaltrials.gov, this particular trial is not currently seeking patients for participation. This study was originally posted on March 24th, 2022 but has since stopped recruiting candidates. However, there are still many other trials (144 in total) that are open for enrollment." - Anonymous Online Contributor
When did Tivanisiran sodium ophthalmic solution receive FDA clearance?
"Tivanisiran sodium ophthalmic solution is in Phase 3 trials, meaning that while there is some data supporting efficacy, multiple rounds of data are needed to support safety." - Anonymous Online Contributor